Poly(ADP-ribose) Polymerase Inhibitors: all 983 studies that test it
Page 2 of 10. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.
- Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic SarcomaRecruitingNCT05952128Phase 2
- OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older AdultsNot yet recruitingNCT05949424Phase 4
- Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
- Letermovir for Primary Prophylaxis of Cytomegalovirus Infection After R+HID-HSCTNot yet recruitingNCT05914675Phase 4
- Estradiol Plus Olaparib for Breast Cancer (PHOEBE)RecruitingNCT05900895Phase 1
- Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue SarcomaRecruitingNCT05894018Phase 2
- Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)RecruitingNCT05891093Phase 3
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingNCT05887609Phase 2
- Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate CancerRecruitingNCT05873192Phase 2
- Improving Peptide Receptor Radionuclide Therapy With PARP InhibitorsRecruitingNCT05870423Phase 1
- Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast CancerRecruitingNCT05834582Phase 2
- Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene MutationRecruitingNCT05761470Phase 2
- PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast CancerRecruitingNCT05759546Phase 2
- Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian Cancer.RecruitingNCT05753826Phase 2
- A Study of Hansoh (HS)-10502 in Patients With Advanced Solid TumorsRecruitingNCT05740956Phase 1
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingNCT05725200Phase 2
- Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCRecruitingNCT05718323Phase 2
- A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric PatientsRecruitingNCT05711667Phase 3
- Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)RecruitingNCT05700721Phase 2
- Combination Therapy in Cancers With Mutations in DNA Repair GenesRecruitingNCT05694715Phase 1
- Pamiparib Combined With Surufatinib for the Neoadjuvant Treatment of Unresectable Ovarian CancerRecruitingNCT05652283Phase 2
- A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian CancerNot yet recruitingNCT05641506Phase 2
- Olaparib Maintenance Therapy in Metastatic Breast CancerRecruitingNCT05629429Phase 2
- Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)RecruitingNCT05623319Phase 2
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingNCT05615818Phase 3
- Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast CancerRecruitingNCT05601440Phase 2
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyRecruitingNCT05585281Phase 2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer: an Open, Single Arm, Multicenter StudyRecruitingNCT05576389Phase 2
- Pembro With Radiation With or Without OlaparibRecruitingNCT05568550Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- Study of the Combination Dostarlimab With Niraparib In Patients With Penile CarcinomaRecruitingNCT05526989Phase 2
- Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck CancerRecruitingNCT05526924Phase 1
- Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast CancerNot yet recruitingNCT05522491Phase 2
- A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCErNot yet recruitingNCT05519670Phase 1/2
- Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast CancerRecruitingNCT05485766Phase 2
- Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT05479487Phase 2
- Study of HRS-1167 as Monotherapy in Patients With Advanced Solid TumorsRecruitingNCT05473624Phase 1
- Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNot yet recruitingNCT05461690Phase 2
- Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Versus ValaciclovirRecruitingNCT05446571Phase 3
- Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
- A Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in Breast Cancer Patients With Germline BRCA MutationsRecruitingNCT05420779Phase 2
- Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate CancerRecruitingNCT05406999Phase 2
- A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing CancersEnrolling by invitationNCT05349409Phase 2
- Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)RecruitingNCT05332561Phase 2
- Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid LeukemiaNot yet recruitingNCT05319249Phase 1/2
- Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) SignatureRecruitingNCT05288127Phase 2
- MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.RecruitingNCT05255471Phase 3
- MITO 35a: Olaparib Maintenance Therapy in Newly Diagnosed BRCA Wild-type Advanced Ovarian, Fallopian Tube and Primitive Peritoneal CancerRecruitingNCT05233982Phase 2
- PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations CarriersNot yet recruitingNCT05232006Phase 2
- PARP Inhibitor Oral Maintenance in Low-Risk Ovarian CancerNot yet recruitingNCT05187208Phase 4
- Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)Not yet recruitingNCT05128734Phase 2
- A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid MalignanciesRecruitingNCT05123482Phase 1/2
- Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and EfficacyRecruitingNCT05101551Phase 1
- Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic CancerRecruitingNCT05093231Phase 2
- ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian CancerRecruitingNCT05071937Phase 2
- Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitorRecruitingNCT05065021Phase 2
- PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine TumoursRecruitingNCT05053854Phase 1
- Selinexor & Talazoparib in Advanced Refractory Solid Tumors; Advanced/Metastatic Triple Negative Breast Cancer (START)RecruitingNCT05035745Phase 1/2
- A Trial of Pamiparib With Tislelizumab in Patients With Advanced Tumours With Homologous Recombination Repair DefectsRecruitingNCT04985721Phase 2
- Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line ChemotherapyRecruitingNCT04978012Phase 2
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate CancerRecruitingNCT04947254Phase 2
- Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing SarcomaRecruitingNCT04901702Phase 1/2
- Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant DeficiencyRecruitingNCT04892693Phase 2
- APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 MutationRecruitingNCT04858334Phase 2
- Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate CancerRecruitingNCT04812366Phase 2
- Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate CancerRecruitingNCT04734730Phase 2
- Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous CarcinomaRecruitingNCT04716686Phase 2
- A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast CancerRecruitingNCT04683679Phase 2
- Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCCRecruitingNCT04681469Phase 2
- TALazoparib and Avelumab as Maintenance Therapy in Platinum-Sensitive Metastatic or Locally Advanced URothelial CarcinomaRecruitingNCT04678362Phase 2
- A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyRecruitingNCT04641247Phase 2
- Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian CancerRecruitingNCT04633239Phase 1
- Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) CancerRecruitingNCT04592211Phase 1/2
- Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian CancerRecruitingNCT04585958Phase 1
- A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLCRecruitingNCT04550104Phase 1
- Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian CancerRecruitingNCT04518501Phase 1/2
- Olaparib in Patients With HRD Malignant MesotheliomaRecruitingNCT04515836Phase 2
- Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal CancerRecruitingNCT04511039Phase 1
- A Trial of AMXI-5001 for Treatment in Patients With Advanced MalignanciesRecruitingNCT04503265Phase 1/2
- A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial CancerRecruitingNCT04486352Phase 1/2
- ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic ProfilingRecruitingNCT04341181Phase 2
- A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationRecruitingNCT04296370Phase 3
- Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)RecruitingNCT04086485Phase 1/2
- Carboplatin or Olaparib for BRcA Deficient Prostate CancerRecruitingNCT04038502Phase 2
- Targeted Pathway Inhibition in Patients With Pancreatic CancerRecruitingNCT04005690Early Phase 1
- Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical TrialRecruitingNCT03990896Phase 2
- Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic CancersRecruitingNCT03968406Phase 1
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate CancerRecruitingNCT03903835Phase 3
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2
- Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian CancerRecruitingNCT03878849Phase 2
- Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene MutationsRecruitingNCT03786796Phase 2
- Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor MalignanciesRecruitingNCT03772561Phase 1
- WIRE - Novel Treatments in Renal Cell CancerRecruitingNCT03741426Phase 2
- PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast CancerRecruitingNCT03740893Phase 2
- Recurrent Ovarian CarcinoSarcoma Anti-pd-1 NiraparibRecruitingNCT03651206Phase 2/3
- Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)RecruitingNCT03486873Phase 3
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)RecruitingNCT03297606Phase 2
- Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast CancerRecruitingNCT03150576Phase 2/3